349611-32-1

Basic information

• Product Name: 3-chloro-N-(6-methyl-1,3-benzothiazol-2-yl)benzamide
• Synonyms: 3-chloro-N-(6-methyl-1,3-benzothiazol-2-yl)benzamide
• CAS NO: 349611-32-1
• Molecular Formula: C₁₅H₁₁ClN₂OS
• Molecular Weight: 302.77864
• Mol File: 349611-32-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-chloro-N-(6-methyl-1,3-benzothiazol-2-yl)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-chloro-N-(6-methyl-1,3-benzothiazol-2-yl)benzamide(349611-32-1)
• EPA Substance Registry System: 3-chloro-N-(6-methyl-1,3-benzothiazol-2-yl)benzamide(349611-32-1)

Safety Data

• Hazardous Substances Data: 349611-32-1(Hazardous Substances Data)

Upstream product

• 2536-91-6 6-methylbenzothiazol-2-ylamine 
• 618-46-2 m-Chlorobenzoyl chloride 

Downstream Products

• 1006292-93-8 ethyl 2-{2-[(3-chlorobenzoyl)imino]-6-methylbenzo[d]thiazol-3(2H)-yl}acetate 

Relevant articles and documents

PHENYLIMIDE-CONTAINING BENZOTHIAZOLE DERIVATIVE OF ITS SALT AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

Provided is a phenylimide-containing benzothiazole derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The phenylimide-containing benzothiazole derivative or its pharmaceutically acceptable salt can selectively inhibit the protein-protein interaction between KRS and a laminin receptor (LR), thereby inhibiting migration of cancer cells. Therefore, the phenylimide-containing benzothiazole derivative or its pharmaceutically acceptable salt may be usefully applied for preventing or treating the diseases associated with cancer cell metastasis.

PHENYLIMIDE-CONTAINING BENZOTHIAZOLE DERIVATIVE OR ITS SALT AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention provides a phenylimide-containing benzothiazole derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The phenylimide-containing benzothiazole derivative or its pharmaceutically acceptable salt can selectively inhibit the protein-protein interaction between KRS and a laminin receptor (LR), thereby inhibiting migration of cancer cells. Therefore, the phenylimide-containing benzothiazole derivative or its pharmaceutically acceptable salt may be usefully applied for preventing or treating the diseases associated with cancer cell metastasis.